fashion -WSS

fashion

author：hotspot 2025-10-02 19:20:32 - browse：51335

Intellia Therapeutics said Sunday that the first 10 patients to receive a CRISPR-based treatment for hereditary angioedema, a genetic disease, saw their swelling attacks — the condition’s hallmark symptom — virtually eliminated for an average of 20 months and counting.

The attacks were reduced by an average of 98%. One patient has remained attack-free for 26 months. Two patients who suffered particularly frequent attacks, experiencing 14 and 16.8 per month, respectively, have now gone more than 20 months since their last attack.

No patient has had an attack in the last 11 months of follow-up, according to the data presented at the European Academy of Allergy and Clinical Immunology Congress. All side effects were either grade 1 or 2 on a 5-grade scale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Personalized medicine goes far beyond genetics

Wikipedia

WSS

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

Flint parents haunted by uncertainty, fears of lead poisoning

The cancer stories no one wants to hear

What will Novo Nordisk's VC do with its influx of cash?

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

It costs an awful lot of money to give away a kidney

entertainment

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

United colonoscopy coverage change 'may cost lives,' doctors say

Will an HIV vaccine ever be a reality?

The cancer drug shortage isn’t new — and neither are the solutions

Heart disease in astronauts blamed on cosmic radiation

FDA approval of Sarepta Duchenne genetic therapy gives me hope

CDC recommends RSV monoclonal antibody for infants

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Physicians aren't 'burning out.' They're suffering from moral injury

BioMarin wins approval for gene therapy to treat hemophilia A

Nobel honors Karikó and Weissman's enduring partnership

knowledge

'Null' research findings aren't empty of meaning. Let's publish them

Setback for rare diseases as Taysha Gene Therapies pulls back

WHO recommends second malaria vaccine

The a glaring gap in research on serious mental illness and primary care

CRISPR base editing slashes cholesterol levels in monkeys

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

hotspot

Wikipedia

hotspot

explore